The SFC-backed vaccine developer has wrapped up its series B-2 round after holding an initial close in early 2019.

AG Capital and Zenrin DataCom were among the backers that helped the mental health assessment software provider close an $11.8m round.

The Novartis-backed retinal disease drug developer has secured $46.9m of series B capital from investors including Johnson & Johnson Innovation – JJDC.

U-M's retinal disease drug developer has secured $46.9m of series B capital from investors including Mints.

The Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics-backed proteomics technology developer has closed the second tranche of the round.

Tencent led a series A2 round for the cell analysis technology developer that included Lilly Asia Ventures and Softbank China Venture Capital.

The Legend Holdings-backed molecular diagnostics tool provider will use the $91.6m to help bring its products to market.

Micromobility, AI-equipped drug discovery, home fitness and cloud kitchens are among the sectors that look promising in 2021.

The Sinopharm-backed antimicrobial drug developer received $107m in a Legend Capital-led round that took its overall funding to $255m.

Lilly Asia Ventures owns more than 9% of the cancer cell therapy developer, which has set a preliminary target of $100m for its initial public offering.